Alpha Diallo
All posts from Alpha Diallo
Alpha Diallo in Alpha Diallo,

La Jolla Pharmaceutical breathing new hope to chronic kidney disease

La Jolla Pharmaceutical Company (NASDAQ:LJPC) shares soaring today after the biopharmaceutical company revealed positive showing for its experimental drug treatment for chronic kidney disease. In the mid-stage study, low doses of the experimental drug significantly increased the speed of blood filtration through the kidneys. Chronic kidney disease according to the National Kidney Foundation affects 26 million Americans. Currently, there are no approved drugs for chronic kidney disease. If the drug is able to survive final stage testing and receive approval from the FDA, it would be huge for society.